Effective Helicobacter pylori diagnosis could save Germany billions
This article was originally published in Clinica
If Germany were to introduce specific disease management procedures incorporating better targeted diagnostic and therapy solutions to treat diseases caused by the Helicobacter pylori bacteria, the health service could make savings of between Euro1.8-2bn ($1.8-2bn), says the diagnostic industry trade association, VDGH. This would correspond to the entire amount that the statutory health insurance funds (GKV) currently pay, statutory health insurance physicians for all laboratory tests, it adds.
You may also be interested in...
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.